Literature DB >> 15980394

In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.

G M Eliopoulos1, M J Ferraro, C B Wennersten, R C Moellering.   

Abstract

The comparative in vitro potency of XRP2868, a new oral semisynthetic streptogramin antibiotic, was evaluated against gram-positive bacteria. XRP2868 inhibited all staphylococci at < or = 1 microg/ml and all non-pneumococcal streptococci at < or = 0.25 microg/ml and was fourfold more potent than quinupristin-dalfopristin against Staphylococcus aureus and Enterococcus faecium.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15980394      PMCID： PMC1168641          DOI： 10.1128/AAC.49.7.3034-3039.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez; Andre Bryskier
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Authors:  G M Eliopoulos; C B Wennersten; H S Gold; T Schülin; M Souli; M G Farris; S Cerwinka; H L Nadler; M Dowzicky; G H Talbot; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin.

Authors:  Kavindra V Singh; George M Weinstock; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 4.  Safety and tolerability of quinupristin/dalfopristin: administration guidelines.

Authors:  E Rubinstein; P Prokocimer; G H Talbot
Journal:  J Antimicrob Chemother       Date:  1999-09       Impact factor: 5.790

5.  Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.

Authors:  Glenn A Pankuch; Linda M Kelly; Gengrong Lin; Andre Bryskier; Catherine Couturier; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

6.  A multicenter evaluation of linezolid antimicrobial activity in North America.

Authors:  Charles H Ballow; Ronald N Jones; Douglas J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  2002-05       Impact factor: 2.803
  6 in total
  4 in total

1.  Activity of a new oral streptogramin, XRP2868, against gram-positive cocci harboring various mechanisms of resistance to streptogramins.

Authors:  Michel Dupuis; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Time-kill activity of the streptogramin NXL 103 against Gram-positive and -negative bacteria.

Authors:  Glenn A Pankuch; Gengrong Lin; Catherine Clark; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

3.  Synergy of streptogramin antibiotics occurs independently of their effects on translation.

Authors:  Jonas Noeske; Jian Huang; Nelson B Olivier; Robert A Giacobbe; Mark Zambrowski; Jamie H D Cate
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 4.  NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA.

Authors:  Amani D Politano; Robert G Sawyer
Journal:  Curr Opin Investig Drugs       Date:  2010-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.